Ankit Shah
Immunology and Microbiology · Purdue University West Lafayette
Publications
83
Citations
1,949
Est. group size
—
Recurring co-author estimate
Active years
24
Publishing since 2003
This publication record spans a mix of topics including drug pharmacokinetics (how drugs move through the body), regulatory drug approval reviews, cancer treatment trials, antimicrobial and anticancer chemical compounds, and clinical case studies in areas like urology. Because the listed titles cover such varied subject matter without a clear unifying research focus, this may reflect contributions across multiple collaborative projects rather than a single dedicated research program. Prospective students should note that the topic relevance scores provided were all listed as 0.00, suggesting limited confidence in the automated subject classification for this profile.
Publication output was low and inconsistent from 2017-2023 but increased sharply in 2024 and 2025, suggesting a recent surge in output rather than steady long-term activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Advancing <scp>PEGylated</scp> Drug Evaluation: A Novel Approach to Pegfilgrastim Pharmacokinetic Assessment
Clinical and Translational Science · 2026
- In vitro and in silico evaluation of fluorinated diphenylamine chalcone derivatives as potential antimalarial and anticancer agents
Scientific Reports · 2025
- FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
Clinical Cancer Research · 2025
- Nano micelle mediated In-Vitro release kinetics of two Biopharmaceutical Classification System (BCS) class II drugs with varying hydrophobicity
Colloid & Polymer Science · 2025
- Exploring the antibacterial activity of novel Schiff bases: A comprehensive and analysis
Total Chemistry · 2025
- TAS102 in combination with oxaliplatin (TASOX) for refractory metastatic colorectal cancer.
Journal of Clinical Oncology · 2025
- Risk factors and outcomes of second primary cancers in colorectal cancer patients by primary tumor site.
Journal of Clinical Oncology · 2025
- Supplementary Table S6 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Figure S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Table S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Figure S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Data from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Table S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Supplementary Table S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
- Methods in molecular biology×5
- Neurotoxicity Research×3
- Journal of Clinical Oncology×3
- Scientific Reports×3
- Nanomedicine Nanotechnology Biology and Medicine×2
- Amanda L. Pendleton
Immunology and Microbiology · Purdue University West Lafayette
- Ajay K. Ghosh
Immunology and Microbiology · Purdue University West Lafayette
- Alka Khaitan
Immunology and Microbiology · Indiana University
- Adarsh Dharan
Immunology and Microbiology · Indiana University
- Amit Sharma
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile